• Peter Benton has been named president of the Phoenix Data Systems division of Bio-Imaging Technologies (Newtown, Pennsylvania). Most recently, he was COO of an eClinical technology services company.

• Paul Kennedy has been named chairman/president/CEO of Ivax Diagnostics (Miami). Kennedy has more than 30 years of senior executive experience with Novo Nordisk France, Abbott France and Boots Co. Ltd., a UK-based healthcare retailer. Ivax also said that Patrice Debregeas has been appointed vice chairman and that Laurent Le Portz has been appointed to the board of directors and its audit and compensation committees. Debregeas is currently president of Debregeas & Associes Pharma, a Paris company specializing in drug development, while Le Portz is an investor with a strong experience in turnaround situations. Kevin Clark, COO of the company who also served as acting CEO since January, will remain with the company as COO as well as COO of ImmunoVision, the company's subsidiary located in Arkansas. Ivax Diagnostics manufactures diagnostic reagents, instrumentation and software in the U.S. and Italy through its three subsidiaries: Diamedix, Delta Biologicals and ImmunoVision.

• Louis Keith has been named president of the First Warning Systems business of Lifeline Biotechnologies (Reno, Nevada). Keith is emeritus professor of obstetrics and gynecology at Northwestern University, and has collaborated for more than a decade with Dr. William Reeves, who developed the First Warning System, publishing various papers with him on the importance of separating the physiologic changes which can be detected before morphologic changes which appear later in a mammogram.

• MicroCHIPS (Bedford, Massachusetts) has formed a scientific advisory board with William Tamborlane, MD, as its founding member. Tamborlane is professor and chief of pediatric endocrinology and diabetes at Yale School of Medicine. The board will support the company in its development of next-generation biosensing and drug delivery devices to increase therapeutic control and effectiveness for people with diabetes, osteoporosis and other diseases. The company's lead program is a long-term implanted continuous glucose monitoring device using its microreservoir technologies.